NCT Number: NCT06740786
Atrial fibrillation (AF) is a common arrhythmia, particularly prevalent in the elderly population. Catheter ablation is a common treatment for AF, but post-ablation recurrence of arrhythmias remains a significant clinical challenge. Dapagliflozin, an SGLT2 inhibitor primarily used for the treatment of type 2 diabetes, has shown potential in the field of cardiology, particularly for treating heart failure patients. Some studies suggest that dapagliflozin may reduce cardiac workload, improve heart function, and could even help in the management of atrial fibrillation. Therefore, this study aims to explore whether dapagliflozin can reduce the recurrence of arrhythmias following atrial fibrillation catheter ablation.
Trial opening soon.
Get Notified18 year and older
All sexes
Interventional
Not applicable
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
First-time Catheter Ablation: Patients undergoing their first atrial fibrillation catheter ablation.
Voluntary Participation: Patients willing to participate and sign informed consent.
Exclusion criteria
Allergy to Dapagliflozin or Similar Drugs: History of allergic reactions to dapagliflozin or other SGLT2 inhibitors.
Other Contraindications to Dapagliflozin: Any other contraindications for dapagliflozin use.
Kidney Function: eGFR < 45 ml/min/1.73m², with severe kidney disease.
This group of patients will receive dapagliflozin treatment after undergoing atrial fibrillation catheter ablation.
Treatment regimen: Dapagliflozin will be administered orally once daily at the recommended dose (e.g., 10 mg/day).
Time frame: Within 12 months, beyond the 3-month blanking period.
The recurrence of atrial arrhythmias within 12 months as assessed by ECG and holter, beyond the 3-month blanking period.
Time frame: Within 12 months, beyond the 3-month blanking period.
The recurrence of atrial fibrillation within 12 months as assessed by ECG and holter, beyond the 3-month blanking period.
Time frame: 12 months post-ablation.
Quality of life was assessed using the Atrial Fibrillation Effect on Quality of Life (AFEQT) questionnaire, measuring changes from baseline to 12 months post-ablation.
Time frame: after 1 year post-ablation
Atrial fibrillation burden is defined as the percentage of time spent in atrial tachyarrhythmia (atrial fibrillation, atrial flutter, or atrial tachycardia) detected by a 7-day single-lead ECG patch monitoring after 1 year post-ablation.
Time frame: 12 months post-ablation.
The safety of dapagliflozin assessed by researchers, including hypoglycemia, Urinary Tract Infections, dehydration and Hypotension,Acute Kidney Injury, diabetic ketoacidosi, cardiovascular events, severe allergic reactions, severe electrolyte Imbalance,etc.
Contact information is provided by the study sponsor or research team.
Xu Liu
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07739888
Arrhythmias, Cardiac, Atrial Fibrillation
View Trial DetailsNCT07740044
Arrhythmias, Cardiac, Arterial Occlusive Diseases
Taizhou, Jiangsu, China
View Trial DetailsNCT07737444
Arrhythmias, Cardiac, Atrial Fibrillation
View Trial DetailsNCT07560644
Arrhythmias, Cardiac, Atrial Fibrillation
View Trial Details